About Cure Pharmaceutical
Cure Pharmaceutical is a company based in Oxnard (United States) founded in 2010. Cure Pharmaceutical has raised $9.65 million across 10 funding rounds from investors including Gene Salkind. The company has 28 employees as of December 31, 2021. Cure Pharmaceutical has completed 2 acquisitions, including Chemistry Holdings and Sera Labs. Cure Pharmaceutical offers products and services including CUREFilm®. Cure Pharmaceutical operates in a competitive market with competitors including Lyndra, i2o Therapeutics, Biora Therapeutics, Cingulate and OnDosis, among others.
- Headquarter Oxnard, United States
- Employees 28 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cure Pharmaceutical
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$9.65 M (USD)
in 10 rounds
-
Latest Funding Round
$11.5 M (USD), Post-IPO
Nov 02, 2020
-
Investors
-
Employee Count
28
as on Dec 31, 2021
-
Investments & Acquisitions
Chemistry Holdings
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cure Pharmaceutical
Cure Pharmaceutical offers a comprehensive portfolio of products and services, including CUREFilm®.
Patented form for rapid sublingual absorption to improve medication efficacy.
Funding Insights of Cure Pharmaceutical
Cure Pharmaceutical has successfully raised a total of $9.65M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $11.5 million completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cure Pharmaceutical
Cure Pharmaceutical has secured backing from 1 investor, including angel investors. Prominent investors backing the company include Gene Salkind.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
GS
Gene Salkind |
-
|
Locked | Locked | Locked |
Investor details for Cure Pharmaceutical
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cure Pharmaceutical
Cure Pharmaceutical has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Chemistry Holdings and Sera Labs.
Investment portfolio details for Cure Pharmaceutical
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of health and wellness products suing cannabis
|
Locked | Locked | 2018 | Locked | |
|
Limited information available
|
Locked | Locked | 2016 | Locked |
Complete acquisition details for Cure Pharmaceutical
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Cure Pharmaceutical
Detailed financials for Cure Pharmaceutical
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cure Pharmaceutical Comparisons
Peer comparison for Cure Pharmaceutical
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cure Pharmaceutical
Cure Pharmaceutical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Lyndra, i2o Therapeutics, Biora Therapeutics, Cingulate and OnDosis, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Innovates long-acting oral therapies to simplify patient medication regimens.
|
|
| Locked | Locked | Locked |
Oral drug delivery solutions are provided via liquid technology platform.
|
|
| Locked | Locked | Locked |
Smart pills are developed for targeted gastrointestinal drug delivery.
|
|
| Locked | Locked | Locked |
Cingulate is focused on developing treatments for ADHD and anxiety.
|
|
| Locked | Locked | Locked |
Oral drug delivery systems for individualized micro-unit dosing are developed.
|
Detailed competitors of Cure Pharmaceutical
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cure Pharmaceutical
Complete news archive for Cure Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cure Pharmaceutical
Cure Pharmaceutical was founded in 2010 and raised its 1st funding round 1 year after it was founded.
Cure Pharmaceutical is headquartered in Oxnard, United States. It is registered at Oxnard, California, United States.
Cure Pharmaceutical is a funded company, having raised a total of $9.65M across 10 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Cure Pharmaceutical is 28.
Cure Pharmaceutical was founded in 2010 in Oxnard, United States, focusing on pharmaceutical drug delivery innovations. Various platforms are developed, including oral thin films, liquid-based encapsulation, transdermal systems using epidermis penetration enhancers, and gastrointestinal delivery methods. Services provided encompass process development, manufacturing, and packaging design to support these technologies. Operations emphasize improved bioavailability compared to traditional forms like tablets and capsules.
Cure Pharmaceutical's top competitors include i2o Therapeutics, Cingulate and PLx Pharma.
Cure Pharmaceutical offers CUREFilm®.
Cure Pharmaceutical has made 2 acquisitions, including Chemistry Holdings, and Sera Labs.
Cure Pharmaceutical has 1 investor. Key investors include Gene Salkind.